Mode
Text Size
Log in / Sign up

GATT reduces IOP in normal-tension glaucoma patients over 24 monthsGATT Surgery Lowers Eye Pressure for Years

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that GATT lowers mean IOP in NTG, but small retrospective series limits certainty.

This single-center retrospective case series investigated the effects of gonioscopy-assisted transluminal trabeculotomy (GATT) in a population of 9 patients with normal-tension glaucoma, comprising 12 eyes. Follow-up assessments were conducted on postoperative day 1, week 1, and months 1, 3, 6, 12, 18, and 24. No comparator group was reported for this analysis.

The primary outcome measured changes in intraocular pressure (IOP) and medication burden. At 24 months, the mean IOP decreased from 17.33 ± 3.53 mmHg to 13.33 ± 2.35 mmHg. The mean reduction was 4.00 ± 2.86 mmHg, with a 95% CI of 2.18–5.82 and a t-value of 4.844. The p-value was not reported. Secondary outcomes included complete and qualified success, postoperative events, and additional interventions or reoperations, though specific data for these were not detailed in the provided results.

Safety and tolerability data were not reported; adverse events, serious adverse events, discontinuations, and general tolerability were not documented. The study limitations include its retrospective case series design, single-center setting, and small sample size of 9 patients and 12 eyes. Funding or conflicts of interest were not reported. Because the study design does not distinguish association from causation and lacks a control group, the observed IOP reduction should be interpreted with caution before altering standard practice.

Imagine waking up with a heavy fog in your eyes. This is what glaucoma feels like for many people. It steals your vision slowly, often without you even noticing.

For years, doctors have relied on eye drops to manage this condition. But what if those drops stop working? Or what if you simply cannot use them anymore?

A new look at a specific surgery offers hope for those struggling with normal-tension glaucoma. This condition happens when eye pressure is low, yet vision still fades.

Normal-tension glaucoma affects thousands of people worldwide. The damage occurs even when pressure readings seem safe. This makes the disease hard to treat with standard methods.

Many patients find themselves stuck on multiple daily drops. This routine is hard to keep up with. Missed doses can lead to rapid vision loss.

Doctors need better options. They need treatments that work long-term without the hassle of daily pills or drops.

The surprising shift

In the past, surgery for this type of glaucoma was risky. It often required cutting into the eye. That carried a high chance of complications.

But here's the twist. A new technique called GATT changes the game. It works from the outside. It does not require a large incision.

This procedure uses a tiny tool to open up the eye's drainage system. Think of it like unclogging a drain pipe. Once the pipe is clear, fluid flows out naturally.

What scientists didn't expect

The biology behind this is simple but clever. Your eye produces fluid constantly. This fluid must drain through a mesh-like structure. In glaucoma, this mesh gets clogged or stiff.

GATT acts like a key turning a lock. It widens the opening so fluid can escape. This lowers the pressure without damaging the delicate nerves inside.

Researchers looked at 12 eyes from nine patients. All had normal-tension glaucoma. They performed the GATT surgery on each eye.

The team followed these patients for two full years. They checked pressure levels at many different times. They also counted how many drops patients needed to use.

The goal was clear: lower pressure and reduce medication. They wanted to see if the surgery held up over time.

The results were promising. At the start, average eye pressure was about 17.3 mmHg. By the end of two years, it dropped to 13.3 mmHg.

That is a significant drop. It means the surgery successfully lowered pressure in most cases. Patients also needed fewer drops to manage their condition.

Some patients needed no drops at all. This is a huge win for quality of life. Less medication means fewer side effects and less daily stress.

This doesn't mean this treatment is available yet.

The study shows great potential, but it is still in the early stages. More data is needed before widespread adoption.

The catch

There is a catch. This study was small. It only included nine patients. We do not know how it works in larger groups.

Also, this was done at one single hospital. Results might differ at other centers. Every patient is different. What works for one might not work for another.

Doctors see this as a valuable tool. It fits well with current treatment plans. It is not a replacement for drops yet. It is an option for those who need more help.

The technique is less invasive than older surgeries. This reduces recovery time and risk. Patients can return to normal life faster.

If you have normal-tension glaucoma, talk to your doctor. Ask if GATT is an option for you. Do not stop your current drops without advice.

This surgery is not for everyone. Your eye structure must be right. Your doctor will decide if you are a good candidate.

Be patient. New treatments take time to prove themselves. Trust the process and your medical team.

This study has limits. It was retrospective, meaning it looked back at past records. This can introduce errors. The sample size was very small.

We cannot say this works for everyone based on this data. More research is needed to confirm safety and long-term success.

Scientists will run larger trials soon. They will test this on more patients. The goal is to get approval for wider use.

If the results hold up, this could change how we treat glaucoma. It offers a real alternative to endless drops.

Stay informed. Ask questions. Your vision is worth the wait for better answers.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
PurposeTo evaluate the 2-year efficacy and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) for normal-tension glaucoma (NTG).MethodsThis single-center retrospective case series included 9 NTG patients (12 eyes) undergoing GATT, with follow-up at postoperative day 1, week 1, and months 1, 3, 6, 12, 18, and 24. Primary outcomes were changes in intraocular pressure (IOP) and IOP-lowering medication burden at 24 months (counted by active ingredients). Complete and qualified success were assessed using strict criteria (from postoperative month 1 onward: IOP 6–15 mmHg and ≥20% reduction from baseline). Postoperative events and additional interventions/reoperations were recorded. Paired t tests or Wilcoxon signed-rank tests were used as appropriate; a one-eye-per-patient sensitivity analysis was performed.ResultsThe median age at surgery was 65 (53–70) years, and most eyes had moderate-to-advanced glaucoma. Mean IOP decreased from 17.33 ± 3.53 mmHg to 13.33 ± 2.35 mmHg at 24 months (mean reduction 4.00 ± 2.86 mmHg; 95% CI 2.18–5.82; t = 4.844; p 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.